REGENXBIO Inc.

In News

Regenxbio gene therapy refiling plan derailed by FDA hold over spine MRI findings - Fierce Biotech

Fierce Biotech - Aug 24, 2026

REGENXBIO Inc. (RGNX) Stock Analysis: Exploring a Potential 188.83% Upside in Biotech Innovation - DirectorsTalk Interviews

DirectorsTalk Interviews - Sep 18, 2026

Transcript : REGENXBIO Inc. Presents at Morgan Stanley 24th Annual Global Healthcare Conference, Sep-16-2026 08 - marketscreener.com

marketscreener.com - Sep 16, 2026

REGENXBIO Announces Proposed Public Offering of Common Stock - PR Newswire

PR Newswire - Jul 16, 2026

REGENXBIO at Morgan Stanley conference: late-stage gene therapy push - Investing.com

Investing.com - Sep 16, 2026

REGENXBIO Inc. stock steadies after Morgan Stanley conference appearance - AD HOC NEWS

AD HOC NEWS - Sep 17, 2026

RGNX: Late-stage gene therapy programs advance toward commercialization, with strong data and funding - TradingView

TradingView - Sep 16, 2026

Regenxbio’s Gene Therapy Faces Another FDA Setback in Hunter Syndrome - Yahoo Finance

Yahoo Finance - Sep 04, 2026

Pharmalittle: We're reading about Medicaid obesity-drug coverage, a Regenxbio gene therapy, and more - STAT

STAT - Aug 24, 2026

Certain Common Stock of REGENXBIO Inc. are subject to a Lock-Up Agreement Ending on 15-SEP-2026. - marketscreener.com

marketscreener.com - Sep 15, 2026

REGENXBIO Strengthens Board of Directors with Appointment of Greg Ciongoli - PR Newswire

PR Newswire - Aug 25, 2026

RGNX: Late-stage gene therapy programs advance toward commercialization, with strong efficacy and safety data - TradingView

TradingView - Sep 16, 2026

Stay Informed

Join our mailing list for the latest report releases and upcoming event notifications.

Headquartered in Boston, Mass., for over 50 years, BCC Research takes pride in being your trusted custom research and data analysts. Our mission is to provide businesses with reputable data and market research reports, so that they gain new perspectives into their field and better understand their target audience. We enable companies to access reliable information, accurate forecasts, and actionable insights, so that they may become leaders in their industry.

AI Sentiment